Kiran Mazumdar-Shaw, CMD, Biocon Ltd, has said that both developed countries and emerging markets were now moving towards generic drugs. She added, with India emerging as biggest and low-cost generic producer, it provides a huge opportunity for India to gain from the growing generic drugs market. She has also demanded that the cost of capital needs to be subsidised, since pharmaceutical was a capital intensive business. Generic drugs is expected to be 40 per cent (value terms) of the global pharmaceutical market by 2015.